Guinness Atkinson Asset Management Inc held its stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 72,510 shares of the biopharmaceutical company’s stock at the end of the second quarter. Gilead Sciences accounts for approximately 3.3% of Guinness Atkinson Asset Management Inc’s holdings, making the stock its 19th biggest holding. Guinness Atkinson Asset Management Inc’s holdings in Gilead Sciences were worth $5,132,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also made changes to their positions in GILD. Harel Insurance Investments & Financial Services Ltd. lifted its stake in Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 1,400 shares during the last quarter. Dubuque Bank & Trust Co. lifted its stake in Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 267 shares during the last quarter. Penserra Capital Management LLC lifted its stake in Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 144 shares during the last quarter. Webster Bank N. A. lifted its stake in Gilead Sciences by 51.7% in the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock valued at $125,000 after buying an additional 624 shares during the last quarter. Finally, American Beacon Advisors Inc. purchased a new stake in Gilead Sciences in the first quarter valued at approximately $143,000. 74.05% of the stock is owned by hedge funds and other institutional investors.
GILD has been the subject of a number of research reports. ValuEngine cut Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. William Blair reiterated an “outperform” rating on shares of Gilead Sciences in a research note on Friday, June 16th. Vetr cut Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $75.40 price objective for the company. in a research note on Wednesday, June 21st. BidaskClub upgraded Gilead Sciences from a “strong sell” rating to a “sell” rating in a research note on Thursday, June 22nd. Finally, Leerink Swann reiterated a “market perform” rating on shares of Gilead Sciences in a research note on Thursday, June 22nd. Eleven analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $83.79.
In other news, EVP James R. Meyers sold 60,000 shares of Gilead Sciences stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $83.19, for a total transaction of $4,991,400.00. Following the transaction, the executive vice president now owns 62,715 shares in the company, valued at $5,217,260.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $71.00, for a total value of $5,206,643.00. Following the transaction, the insider now owns 3,199,969 shares in the company, valued at approximately $227,197,799. The disclosure for this sale can be found here. Insiders have sold 466,819 shares of company stock worth $36,740,240 in the last quarter. 1.30% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION WARNING: This piece was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://www.chaffeybreeze.com/2017/09/17/guinness-atkinson-asset-management-inc-holds-stake-in-gilead-sciences-inc-gild.html.
Gilead Sciences, Inc. (NASDAQ GILD) traded up 0.09% during trading on Friday, reaching $82.36. The company had a trading volume of 12,401,948 shares. The stock has a 50 day moving average price of $77.16 and a 200 day moving average price of $70.20. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $86.27. The firm has a market capitalization of $107.56 billion, a price-to-earnings ratio of 8.95 and a beta of 1.19.
Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The business had revenue of $7.14 billion for the quarter, compared to analysts’ expectations of $6.35 billion. During the same period in the previous year, the firm posted $3.08 EPS. The company’s quarterly revenue was down 8.2% on a year-over-year basis. On average, equities research analysts predict that Gilead Sciences, Inc. will post $8.75 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 28th. Stockholders of record on Friday, September 15th will be issued a dividend of $0.52 per share. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.53%. Gilead Sciences’s dividend payout ratio is 22.58%.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.